Weekly Recap: Isembyld approved, down >12% and Truist raises PT to $77

Shares of Scholar Rock Holding Corp. (NASDAQ:SRRK) slid over 12% after FDA approval of Isembyld for SMA patients on SMN2-targeted therapy, even as Truist kept a Buy and nudged its $76 target to $77 and the company granted 83,102 inducement awards to new hires.Previous Week RecapThis is an AI-genera…